News | July 26, 2025
RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Need to harmonize traditional and modern medicine to combat alarming health problems
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The price revision, effective April 3, 2026, will bring the innovator molecule within the reach of a significantly larger patient base across the country
This marks a meaningful step in the company's continued expansion in the region
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
Subscribe To Our Newsletter & Stay Updated
